Literature DB >> 33498178

Spinal PAR2 Activation Contributes to Hypersensitivity Induced by Peripheral Inflammation in Rats.

Petra Mrozkova1, Diana Spicarova1, Jiri Palecek1.   

Abstract

The mechanisms of inflammatory pain need to be identified in order to find new superior treatments. Protease-activated receptors 2 (PAR2) and transient receptor potential vanilloid 1 (TRPV1) are highly co-expressed in dorsal root ganglion neurons and implicated in pain development. Here, we examined the role of spinal PAR2 in hyperalgesia and the modulation of synaptic transmission in carrageenan-induced peripheral inflammation, using intrathecal (i.t.) treatment in the behavioral experiments and recordings of spontaneous, miniature and dorsal root stimulation-evoked excitatory postsynaptic currents (sEPSCs, mEPSCs and eEPSCs) in spinal cord slices. Intrathecal PAR2-activating peptide (AP) administration aggravated the carrageenan-induced thermal hyperalgesia, and this was prevented by a TRPV1 antagonist (SB 366791) and staurosporine i.t. pretreatment. Additionally, the frequency of the mEPSC and sEPSC and the amplitude of the eEPSC recorded from the superficial dorsal horn neurons were enhanced after acute PAR2 AP application, while prevented with SB 366791 or staurosporine pretreatment. PAR2 antagonist application reduced the thermal hyperalgesia and decreased the frequency of mEPSC and sEPSC and the amplitude of eEPSC. Our findings highlight the contribution of spinal PAR2 activation to carrageenan-induced hyperalgesia and the importance of dorsal horn PAR2 and TRPV1 receptor interactions in the modulation of nociceptive synaptic transmission.

Entities:  

Keywords:  PAR2; TRPV1; inflammatory pain; nociception; peripheral inflammation; spinal cord; superficial dorsal horn; synaptic transmission; thermal hyperalgesia

Mesh:

Substances:

Year:  2021        PMID: 33498178      PMCID: PMC7863954          DOI: 10.3390/ijms22030991

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  62 in total

1.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.

Authors:  M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Acute PAR2 activation reduces GABAergic inhibition in the spinal dorsal horn.

Authors:  Zhangxiang Huang; Kunming Tao; Hai Zhu; Xuerong Miao; Zhengmeng Wang; Weifeng Yu; Zhijie Lu
Journal:  Brain Res       Date:  2011-10-06       Impact factor: 3.252

3.  Increased expression of protease-activated receptor 2 and 4 within dorsal root ganglia in a rat model of bone cancer pain.

Authors:  Yanju Bao; Wei Hou; Liping Yang; Rui Liu; Yebo Gao; Xiangying Kong; Zhan Shi; Weidong Li; Honggang Zheng; Shulong Jiang; Baojin Hua
Journal:  J Mol Neurosci       Date:  2014-10-26       Impact factor: 3.444

4.  A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.

Authors:  Prisca Honore; Carol T Wismer; Joe Mikusa; Chang Z Zhu; Chengmin Zhong; Donna M Gauvin; Arthur Gomtsyan; Rachid El Kouhen; Chih-Hung Lee; Kennan Marsh; James P Sullivan; Connie R Faltynek; Michael F Jarvis
Journal:  J Pharmacol Exp Ther       Date:  2005-04-18       Impact factor: 4.030

5.  Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain.

Authors:  Y Chen; C Yang; Z J Wang
Journal:  Neuroscience       Date:  2011-07-14       Impact factor: 3.590

6.  Pain responses to protease-activated receptor-2 stimulation in the spinal cord of naïve and arthritic rats.

Authors:  Flora Lucena; Jason J McDougall
Journal:  Neurosci Lett       Date:  2020-09-16       Impact factor: 3.046

7.  Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons.

Authors:  Kwai A Alier; Jaclyn A Endicott; Patrick L Stemkowski; Nicolas Cenac; Laurie Cellars; Kevin Chapman; Patricia Andrade-Gordon; Nathalie Vergnolle; Peter A Smith
Journal:  J Pharmacol Exp Ther       Date:  2007-10-05       Impact factor: 4.030

8.  Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome.

Authors:  Nestor N Jimenez-Vargas; Luke A Pattison; Peishen Zhao; TinaMarie Lieu; Rocco Latorre; Dane D Jensen; Joel Castro; Luigi Aurelio; Giang T Le; Bernard Flynn; Carmen Klein Herenbrink; Holly R Yeatman; Laura Edgington-Mitchell; Christopher J H Porter; Michelle L Halls; Meritxell Canals; Nicholas A Veldhuis; Daniel P Poole; Peter McLean; Gareth A Hicks; Nicole Scheff; Elyssa Chen; Aditi Bhattacharya; Brian L Schmidt; Stuart M Brierley; Stephen J Vanner; Nigel W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

9.  TRPV1 antagonist attenuates postoperative hypersensitivity by central and peripheral mechanisms.

Authors:  Eva Uchytilova; Diana Spicarova; Jiri Palecek
Journal:  Mol Pain       Date:  2014-11-17       Impact factor: 3.395

10.  TRPV1 SUMOylation regulates nociceptive signaling in models of inflammatory pain.

Authors:  Yan Wang; Yingwei Gao; Quan Tian; Qi Deng; Yangbo Wang; Tian Zhou; Qiang Liu; Kaidi Mei; Yingping Wang; Huiqing Liu; Ruining Ma; Yuqiang Ding; Weifang Rong; Jinke Cheng; Jing Yao; Tian-Le Xu; Michael X Zhu; Yong Li
Journal:  Nat Commun       Date:  2018-04-18       Impact factor: 14.919

View more
  1 in total

1.  Hypersensitivity Induced by Intrathecal Bradykinin Administration Is Enhanced by N-oleoyldopamine (OLDA) and Prevented by TRPV1 Antagonist.

Authors:  Eva Uchytilova; Diana Spicarova; Jiri Palecek
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.